{
    "nct_id": "NCT04261075",
    "official_title": "A Phase 1, First-in-Human, Multicenter, Open-label, Dose-escalation Study of IPH5201 as Monotherapy or in Combination With Durvalumab ± Oleclumab in Advanced Solid Tumors",
    "inclusion_criteria": "* Adult subjects; age ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Subjects diagnosed with advanced solid tumors.\n* For Part 1 and Part 2 (IPH5201 in monotherapy or combined with durvalumab):Subjects must be refractory to standard therapy or for which no standard therapy exists.\n* For Part 3 (IPH5201 combined with durvalumab and oleclumab): Subjects must have received and radiologically progressed on 1 prior line of systemic therapy for metastatic pancreatic ductal adenocarcinoma.\n* Subjects must have at least 1 measurable lesion according to RECIST v1.1.\n* Subjects must provide tumor specimens .\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 101 Years",
    "exclusion_criteria": "* Receipt of any conventional or investigational anticancer therapy (anti-CTLA-4, anti-PD-1, anti-PD-L1 antibodies) within 21 days of the planned first dose.\n* Receipt of agents targeting CD73, CD39, or adenosine receptors.\n* Concurrent enrollment in another therapeutic clinical study.\n* Any toxicity (excluding alopecia) from prior standard therapy that has not been completely resolved to baseline at the time of consent.\n\n  * No toxicity leading to permanent discontinuation of prior IO therapy\n  * Subjects must not have required the use of additional immunosuppression other than corticosteroids\n* Active or prior documented autoimmune or inflammatory disorders within the past 5 years\n* Cardiac and vascular criteria:\n\n  * Presence of myocardial infarction or unstable angina , or stroke, within 6 months.\n  * Congestive heart failure, serious cardiac arrhythmia requiring medication, or uncontrolled hypertension\n  * History of severe hypertension\n  * History of any grade of blood clot within 6 months\n* Active infection, including tuberculosis; hepatitis B virus (HBV); hepatitis C virus (HCV); or human immunodeficiency virus (HIV)\n* Uncontrolled illness including certain lung diseases, uncontrolled diabetes, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study.\n* Other invasive malignancy within 2 years.\n* Major surgery within 28 days prior to first dose\n* Female subjects who are pregnant or breast feeding",
    "miscellaneous_criteria": ""
}